Get access

Structural alterations in chronic lymphocytic leukaemia. Cytogenetic and FISH analysis

Authors

Errata

This article is corrected by:

  1. Errata: Erratum: Structural alterations in chronic lymphocytic leukaemia. Cytogenetic and FISH analysis Volume 31, Issue 3, 168, Article first published online: September 2013

  • This article was published online on 07 September 2012. Errors were subsequently identified in Table 2. This notice is included in the online version to indicate that it has been corrected [24 October 2012].

Correspondence to: Irma Slavutsky, Laboratorio de Genética, Instituto de Medicina Experimental (IMEX), CONICET - Academia Nacional de Medicina, Pacheco de Melo 3081, 1425 - Buenos Aires, Argentina.

E-mail: islavutsky@hematologia.anm.edu.ar

Abstract

In this study, we described cytogenetics and fluorescence in situ hybridization (FISH) analysis performed in chronic lymphocytic leukaemia (CLL) patients with structural alterations. Results were correlated with clinical characteristics. A total of 38 CLL patients: 16 cases with complex and 22 with simple karyotypes were studied. For comparison of clinical parameters, a control group of 78 CLL patients with normal karyotype and without FISH genomic alterations were also evaluated. We found 38 structural abnormalities not previously described in the literature, 28 (74%) of them were translocations. In cases with complex karyotypes, chromosomes 6, 8 and 13 were the most frequently involved in new alterations (nine each), followed by chromosomes 12, 14 and 15 (six each). Chromosome 8p was particularly involved in losses, being 8p21-pter the commonest region of overlap. Cases with simple karyotypes, showed del(6q) as the most frequent alteration (39%). Del(9)(q11) was recurrent in our series. Analysis of clinical parameters showed significant differences in white blood count (p = 0.005) and platelet count (p = 0.015) between patients with structural alterations and the control group. In addition, patients with structural alterations had a significantly shorter time to first treatment (TFT) (29 months) than the control group (69 months) (p = 0.037). Cases with complex karyotypes had a lower proportion of patients in Rai 0 clinical stage (15.4% vs 75%) (p = 0.005) and higher β2 microglobulin levels (3.3 vs 2.5 µg/mL) (p = 0.037) than those with simple karyotypes. Furthermore, a shorter TFT (13 months) and overall survival (56 months) in the complex karyotypes group compared with controls (69 and 144 months, respectively) (p = 0.015 and p = 0.005, respectively) were also found. Our results support the importance of cytogenetic analysis for clinical outcome in CLL and suggest that the diversity of genomic alterations is much greater than previously appreciated. Copyright © 2012 John Wiley & Sons, Ltd.

Get access to the full text of this article

Ancillary